




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07C 237/20, A61K 31/16</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/35123</b> <b>(43) International Publication Date:</b> 15 July 1999 (15.07.99)
<b>(21) International Application Number:</b> PCT/EP98/08158 <b>(22) International Filing Date:</b> 12 December 1998 (12.12.98) <b>(30) Priority Data:</b> 9727521.8 31 December 1997 (31.12.97) GB <b>(71) Applicant (for all designated States except US):</b> NEWRON PHARMACEUTICALS S.P.A. [IT/IT]; Via R. Lepetit, 34, I-21040 Gerenzano (IT). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> PEVARELLO, Paolo [IT/IT]; Piazza San Pietro in Ciel D'Oro, 7/A, I-27100 Pavia (IT). VARASI, Mario [IT/IT]; Via Giambellino, 80, I-20146 Milan (IT). SALVATI, Patricia [IT/IT]; Via Valera, 16/C, I-20020 Arese (IT). POST, Claes [SE/SE]; Nässelvägen 5, S-193 34 Sigtuna (SE). <b>(74) Agent:</b> MINARDI, Giovanni; Newron Pharmaceuticals S.p.A., Via R. Lepetit, 34, I-21040 Gerenzano (IT).		<b>(81) Designated States:</b> AL, BA, BG, BR, CA, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KR, LC, LK, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

**(54) Title:** SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS

**(57) Abstract**

Compounds which are substituted 2-benzylamino-2-phenyl-acetamide compounds of formula (I) wherein: n is zero, 1, 2 or 3; X is -O-, -S-, -CH<sub>2</sub>- or -NH-; each of R, R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub>, independently, is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkoxy or trifluoromethyl; each of R<sub>4</sub> and R<sub>5</sub>, independently, is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>3</sub>-C<sub>7</sub> cycloalkyl; or pharmaceutically acceptable salts thereof, are useful in treating conditions such as chronic or neuropathic pain.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AL</b>	Albania	<b>ES</b>	Spain	<b>LS</b>	Lesotho	<b>SI</b>	Slovenia
<b>AM</b>	Armenia	<b>FI</b>	Finland	<b>LT</b>	Lithuania	<b>SK</b>	Slovakia
<b>AT</b>	Austria	<b>FR</b>	France	<b>LU</b>	Luxembourg	<b>SN</b>	Senegal
<b>AU</b>	Australia	<b>GA</b>	Gabon	<b>LV</b>	Latvia	<b>SZ</b>	Swaziland
<b>AZ</b>	Azerbaijan	<b>GB</b>	United Kingdom	<b>MC</b>	Monaco	<b>TD</b>	Chad
<b>BA</b>	Bosnia and Herzegovina	<b>GE</b>	Georgia	<b>MD</b>	Republic of Moldova	<b>TG</b>	Togo
<b>BB</b>	Barbados	<b>GH</b>	Ghana	<b>MG</b>	Madagascar	<b>TJ</b>	Tajikistan
<b>BE</b>	Belgium	<b>GN</b>	Guinea	<b>MK</b>	The former Yugoslav Republic of Macedonia	<b>TM</b>	Turkmenistan
<b>BF</b>	Burkina Faso	<b>GR</b>	Greece	<b>ML</b>	Mali	<b>TR</b>	Turkey
<b>BG</b>	Bulgaria	<b>HU</b>	Hungary	<b>MN</b>	Mongolia	<b>TT</b>	Trinidad and Tobago
<b>BJ</b>	Benin	<b>IE</b>	Ireland	<b>MR</b>	Mauritania	<b>UA</b>	Ukraine
<b>BR</b>	Brazil	<b>IL</b>	Israel	<b>MW</b>	Malawi	<b>UG</b>	Uganda
<b>BY</b>	Belarus	<b>IS</b>	Iceland	<b>MX</b>	Mexico	<b>US</b>	United States of America
<b>CA</b>	Canada	<b>IT</b>	Italy	<b>NE</b>	Niger	<b>UZ</b>	Uzbekistan
<b>CF</b>	Central African Republic	<b>JP</b>	Japan	<b>NL</b>	Netherlands	<b>VN</b>	Viet Nam
<b>CG</b>	Congo	<b>KE</b>	Kenya	<b>NO</b>	Norway	<b>YU</b>	Yugoslavia
<b>CH</b>	Switzerland	<b>KG</b>	Kyrgyzstan	<b>NZ</b>	New Zealand	<b>ZW</b>	Zimbabwe
<b>CI</b>	Côte d'Ivoire	<b>KP</b>	Democratic People's Republic of Korea	<b>PL</b>	Poland		
<b>CM</b>	Cameroon	<b>KR</b>	Republic of Korea	<b>PT</b>	Portugal		
<b>CN</b>	China	<b>KZ</b>	Kazakstan	<b>RO</b>	Romania		
<b>CU</b>	Cuba	<b>LC</b>	Saint Lucia	<b>RU</b>	Russian Federation		
<b>CZ</b>	Czech Republic	<b>LI</b>	Liechtenstein	<b>SD</b>	Sudan		
<b>DE</b>	Germany	<b>LK</b>	Sri Lanka	<b>SE</b>	Sweden		
<b>DK</b>	Denmark	<b>LR</b>	Liberia	<b>SG</b>	Singapore		
<b>EE</b>	Estonia						

**SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS**

The present invention relates to novel substituted 2-benzylamino-2-phenyl-acetamide compounds, to a process for their preparation, to pharmaceutical composition containing them and to their use as therapeutic agents.


In particular, the compounds provided by the present invention are sodium channel blockers, and thus exhibit useful pharmacological properties, especially for the treatment and alleviation of chronic and neuropathic pain.

Chronic and neuropathic pain are associated with prolonged tissue damage or injuries to the peripheral or central nervous system and result from a number of complex changes in nociceptive pathways, including ion channel function.

Clinical manifestations of chronic pain include a sensation of burning or electric shock, feelings of bodily distortion, allodynia and hyperpathia.

Despite the large number of available analgesics, their use is limited by severe side effects and modest activity in some pain conditions. Therefore there is still a clear need to develop new compounds.

Accordingly, one object of the present invention is to provide novel compound having the following formula (I)



wherein:

n is zero, 1, 2 or 3;

X is -O-, -S-, -CH<sub>2</sub>- or -NH-;

each of R, R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub>, independently, is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkoxy or trifluoromethyl; each of R<sub>4</sub> and R<sub>5</sub>, independently, is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>3</sub>-C<sub>7</sub> cycloalkyl; and the pharmaceutically acceptable salts thereof.

A -(CH<sub>2</sub>)<sub>n</sub>- chain may be a branched or straight chain.

Alkyl and alkoxy groups may be branched or straight groups.

Representative examples of C<sub>1</sub>-C<sub>6</sub> alkyl groups include C<sub>1</sub>-C<sub>4</sub> alkyl groups such as methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl.

Representative examples of C<sub>1</sub>-C<sub>6</sub> alkoxy groups include C<sub>1</sub>-C<sub>4</sub> alkoxy groups such as methoxy and ethoxy.

A C<sub>3</sub>-C<sub>7</sub> cycloalkyl group is for instance cyclopropyl, cyclopentyl or cyclohexyl, in particular cyclopentyl or cyclohexyl.

A halogen atom is fluorine, bromine, chlorine or iodine, in particular, chlorine or fluorine.

Pharmaceutically acceptable salts of the compounds of the invention include acid addition salts with inorganic, e.g. nitric, hydrochloric, hydrobromic, sulphuric, perchloric and phosphoric acids or organic, e.g. acetic, trifluoroacetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic and salicylic acids.

The compounds of the invention have asymmetric carbon atoms and therefore they can exist either as racemic mixtures or as individual optical isomers (enantiomers).

Accordingly, the present invention also include within its scope all the possible isomers and their mixtures and both the metabolites and the pharmaceutically acceptable bioprecursors (otherwise known as pro-drugs) of the compounds of the invention.

Preferred compounds of the invention are the compounds of formula (I) wherein

n is 1 or 2;

X is -O-;

each of R, R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub>, independently, is hydrogen, or halogen;

- 5 R<sub>4</sub> and R<sub>5</sub> are hydrogen; and the pharmaceutically acceptable salts thereof.

Examples of specific compounds of the invention are:

2-[4-benzyloxybenzylamino]-2-phenyl-acetamide;

- 10 2-[4-(3-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide;

2-[4-(3-chlorobenzyloxy)benzylamino]-2-phenyl-acetamide;

2-[4-(3-bromobenzyloxy)benzylamino]-2-phenyl-acetamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide;

- 15 2-[4-(3-fluorobenzyloxy)benzylamino]-2-(2-fluorophenyl)-  
acetamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-  
acetamide; and

- 2-[4-(3-chlorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-  
acetamide, if the case either as a single isomer or as a  
20 mixture thereof, and the pharmaceutically acceptable salts  
thereof.

- Object of the present invention is also to provide a  
compound of formula (I), as defined above, or a  
25 pharmaceutically acceptable salt thereof for use as a  
therapeutic substance, in particular for treating chronic  
and neuropathic pain.

- An aspect of this invention relates to the use of a  
30 compound of formula (I), as defined above, or a  
pharmaceutically acceptable salt thereof in the manufacture  
of a medicament for use in treating chronic and neuropathic  
pain.

A further aspect of this invention relates to a method of treating a mammal, including humans, in need of a sodium channel-blocking agent, said method comprising administering thereto an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Neuropathic pain conditions in a mammal can thus be alleviated and treated. Examples of neuropathic pain conditions responsive to sodium channel-blocking agents include:

- peripheral neuropathies, such as trigeminal neuralgia, postherpetic neuralgia, diabetic neuropathy, glossopharyngeal neuralgia, radiculopathy, and neuropathy secondary to metastatic infiltration, adiposis dolorosa and burn pain; and
- central pain conditions following stroke, thalamic lesions and multiple sclerosis.

'Treatment' as used herein covers any treatment of a condition in a mammal, particularly a human, and includes:


- (i) preventing the disease from occurring in a subject which may be predisposed to the disease, but has not yet been diagnosed as having it;
- (ii) inhibiting the condition, i.e., arresting its development; or
- (iii) relieving the condition, i.e., causing regression of the disease.

The term 'disease state which is alleviated by treatment with a sodium channel blocker' as used herein is intended to cover all disease states which are generally acknowledged in the art to be usefully treated with sodium channel blockers in general, and those disease states which have been found to be usefully treated by the specific sodium channel blocker of our invention, the compound of formula (I).


The compounds of the invention and the salts thereof can be

obtained, for instance, by a process comprising:

a) reacting a compound of formula (II)




wherein n, R<sub>2</sub>, R<sub>3</sub> and X are as defined above, with a  
5 compound of formula (III)





wherein R, R<sub>1</sub> and R<sub>4</sub> are as defined above, thus obtaining a  
compound of formula (I) in which R<sub>5</sub> is hydrogen; or

b) reacting a compound of formula (IV)



10

wherein R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, n and X are as defined above, with  
a compound of formula (V), (VI) or (VII)



15

wherein W is a halogen atom; R'<sub>5</sub> is a C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>3</sub>-C<sub>7</sub>

cycloalkyl and R''<sub>s</sub> is hydrogen or C<sub>1</sub>-C<sub>5</sub> alkyl, and p is 2-6, thus obtaining a compound of the invention in which R<sub>s</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>3</sub>-C<sub>7</sub> cycloalkyl; and, if desired, converting a compound of the invention into another compound of the invention and/or, if desired, converting a compound of the invention into a pharmaceutically acceptable salt and/or, if desired, converting a salt into a free compound.

All the processes described hereabove are analogy processes and can be carried out according to well known methods in organic chemistry.

A compound of formula (IV) is a compound of formula (I) in which R<sub>s</sub> is hydrogen.

The reaction of a compound of formula (II) with a compound of formula (III) to give a compound of formula (I) or (IV) is a reductive amination reaction which can be carried out according to well known methods. According to a preferred embodiment of the invention it may be performed under nitrogen atmosphere, in a suitable organic solvent, such as an alcohol, e.g. a lower alkanol, in particular methanol, or in acetonitrile, at a temperature ranging from about 0°C to about 40°C, in the presence of a reducing agent, the most appropriate being sodium cyanoborohydride.

Occasionally molecular sieves can be added to the reaction mixture for facilitating the reaction.

In a compound of formula (V) the halogen W is preferably iodine. The alkylation reaction of a compound of formula (IV) with a compound of formula (V) can be carried out in a suitable organic solvent, such as an alcohol, e.g. methanol, ethanol or isopropanol, in particular in ethanol, at a temperature ranging from about 0°C to about 50°C.

The alkylation reaction of a compound of formula (IV) with an aldehyde of formula (VI) or (VII) can be carried out in a suitable organic solvent, such as an alcohol, e.g. methanol, ethanol or acetonitrile in the presence of a suitable reducing agent, such as sodium cyanoborohydride, at a temperature ranging from about 0°C to about 30°C.



A compound of the invention can be converted, as stated above, into another compound of the invention by known methods. Process-variant b) above may be regarded as an example of optional conversion of a compound of the invention into another compound of the invention.

Also the optional salification of a compound of the invention as well as the conversion of a salt into the free compound may be carried out by conventional methods.

The compounds of formula (II) and (III), (V), (VI) and (VII) are known compounds or can be obtained by known methods.

When in the compounds of the present invention and in the intermediate-products thereof, groups are present, which need to be protected before submitting them to the hereabove illustrated reactions, they may be protected before being reacted and then deprotected according to methods well known in organic chemistry.

#### **PHARMACOLOGY**

As stated above, the compounds of the invention are sodium channel-blocking agents, as proven for instance by the fact that they bind to site-2 (labeled by <sup>3</sup>H-Batrachotoxin) on the rat brain sodium channel.

Interaction of the compounds with the site 2 of the sodium channel was evaluated in rat brain membranes using the <sup>3</sup>H-batrachotoxin as ligand, according to published methods (Catterall, W.A., J. Biol. Chem., 1981, **256**, 8922-8927).

For instance, for the representative compound of the (R)-2-[4-(3-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide, methanesulfonate (internal code PNU 190296 E) the following test data were obtained.

Table 1: Na <sup>+</sup> channel block	
Compound	<sup>3</sup> H-Batrachotoxin binding (μM)
PNU 190296E	0.39

In view of their biological activity, the compounds of the invention are useful in therapy in the regulation of physiological phenomena related to sodium channel blockade, including arrhythmia, convulsion, pain associated with damage or permanent alteration of the peripheral or central nervous system, for example peripheral neuropathies, such as trigeminal neuralgia, postherapeutic neuralgia, diabetic neuropathy, raticulopathy, glossopharyngeal neuralgia, and neuropathy secondary to metastatic infiltration, adiposis dolorosa, and burn pain; and central pain conditions following stroke, thalamic lesions and multiple sclerosis. The conditions of a patient in need of a sodium channel-blocking agent may thus be improved.

The compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscularly, or by intravenous injection or infusion.

The dosage depends on the age, weight, conditions of the patient and on the administration route; for example, the dosage adopted for oral administration to adult humans e.g. for the representative compound of the invention (R)-2-[4-(3-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide may range from about 1 to about 500 mg pro dose, from 1 to 5 times daily.

The invention includes pharmaceutical compositions comprising a compound of the invention, as an active principle, in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent).

The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.

For example, the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, destrose,

saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; desegregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film-coating processes.

The liquid dispersion for oral administration may be e.g. syrups, emulsions and suspension.

The syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

The suspension and the emulsion may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.

The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

The suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.

The following examples illustrate but do not limit the invention.

**Example 1**

5 1. D-phenylglycinamide

30 g (0.149 mol) of D-phenylglycine methyl ester, hydrochloride were dissolved in dioxane (90 mL), then 90 mL of 30%  $\text{NH}_4\text{OH}$  solution were added dropwise. The mixture was stirred overnight, evaporated and the crude residue flash-  
10 chromatographed on silica gel using dichloromethane/methanol/30%  $\text{NH}_4\text{OH}$ ; 165/35/3. The white solid obtained was dissolved in abs. EtOH and acidified with an excess of 10% HCl in EtOH. The solution was evaporated, taken up with diethyl ether ( $\text{Et}_2\text{O}$ ), the white  
15 solid precipitated was filtered and washed with  $\text{Et}_2\text{O}$ , yielding 12.2 g (69%) of pure compound.

$[\alpha]_D^{25} +99.6$  (c=1.1, MeOH)

20 2. (R)-2-[4-(3-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide, methanesulfonate

A mixture of D-phenylglycinamide hydrochloride (4.45 g; 0.022 mol) and 3A molecular sieves (4.45 g) in MeOH (150 mL) was stirred under nitrogen for 10 minutes, then treated with sodium cyanoborohydride (1.09 g; 0.016 mol) and 4-(3-  
25 fluorobenzyloxy)benzaldehyde (5 g; 0.022 mol). The mixture was stirred at room temperature for 4 hours, then filtered, the residue evaporated and flash-chromatographed on silica gel using dichloromethane/methanol/30%  $\text{NH}_4\text{OH}$ ; 95/5/0.5) as eluant. 5.3 g (53%) of a crystalline white solid were  
30 obtained after treatment with an excess of methanesulfonic acid in ethyl acetate and filtration.

m.p. 227-231°C;

$[\alpha]_D^{25} -50.2$  (c = 1.1, AcOH);

Elemental Analysis:

35 Atom Calc. Found

C	59.98	59.17
H	5.47	5.46
N	6.08	6.04
S	6.96	7.30

5

Analogously, starting from the appropriate aldehyde and aminoamide, the following compounds can be prepared:

2-[4-benzyloxybenzylamino]-2-phenyl-acetamide  
methanesulfonate;

10 2-[4-(3-chlorobenzyloxy)benzylamino]-2-phenyl-acetamide  
methanesulfonate;

2-[4-(3-bromobenzyloxy)benzylamino]-2-phenyl-acetamide  
methanesulfonate;

15 2-[4-(2-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide  
methanesulfonate;

2-[4-(3-fluorobenzyloxy)benzylamino]-2-(2-fluorophenyl)-  
acetamide methanesulfonate;

2-[4-(3-fluorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-  
acetamide methanesulfonate;

20 2-[4-(3-chlorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-  
acetamide methanesulfonate;

2-[4-(3-fluorobenzylamino)benzylamino]-2-phenyl-acetamide  
methanesulfonate; and

25 2-[4-(3-fluorobenzylthio)benzylamino]-2-phenyl-acetamide  
methanesulfonate.

### Example 2

(R)-2-[[4-(3-fluorophenyloxy)benzyl]-2-methyl-amino]-2-  
phenyl-acetamide

30 4 g (0.011 mol) of (R)-2-[4-(3-fluorophenyloxy)benzylamino]-  
2-phenyl-acetamide were dissolved in methanol (50 mL) and  
1.8 g (0.013 mol) of anhydrous potassium carbonate were  
added to the solution. Methyl iodide (1.5 mL; 0.025 mol)

was dropped into the mixture which was stirred for 2 hours at room temperature and then evaporated to dryness. The crude residue was chromatographed on silica gel (eluant: chloroform/methanol; 95/5). 2.11 g (51%) of (R)-2-[[4-(3-fluorophenyloxy)benzyl]-2-methyl-amino]-2-phenyl-acetamide  
5 were obtained.

Elemental Analysis:

	Atom	Calc.	Found
	C	73.00	73.35
10	H	6.13	6.18
	F	5.02	5.00
	N	7.40	7.29

Analogously, the following compounds can be obtained and,  
15 if required, salified with a suitable acidic agent according to known methods:

(R)-2-[[4-(3-chlorophenyloxy)benzyl]-2-methyl-amino]-2-phenyl-acetamide;  
(S)-2-[[4-(3-fluorophenyloxy)benzyl]-2-methyl-amino]-2-phenyl-acetamide;  
20 (R)-2-[[4-(3-bromophenyloxy)benzyl]-2-methyl-amino]-2-phenyl-acetamide;  
(R)-2-[[4-(3-fluorophenyloxy)benzyl]-2-ethyl-amino]-2-phenyl-acetamide;  
25 (R)-2-[(4-phenyloxybenzyl)-2-methyl-amino]-2-phenyl-acetamide;  
(S)-2-[(4-phenyloxybenzyl)-2-methyl-amino]-2-phenyl-acetamide; and  
(R)-2-[[4-(3-fluorophenyloxy)benzyl]-2-cyclopropyl-amino]-2-phenyl-acetamide.  
30

### Example 3


With the usual methods of pharmaceutical technique,

preparation can be made of capsules having the following composition:

2-[4-(3-fluorobenzyloxy)benzylamino]-2-	
phenyl-acetamide, methanesulfonate	50 mg
5 Talc	2 mg
Corn starch	2 mg
Microcristalline cellulose	6 mg
Magnesium stearate	1 mg

CLAIMS

1. A compound which is a substituted 2-benzylamino-2-phenyl acetamide of formula (I)



5

wherein:

n is zero, 1, 2 or 3;

X is -O-, -S-, -CH<sub>2</sub>- or -NH-;

each of R, R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub>, independently, is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkoxy or trifluoromethyl;  
 10 each of R<sub>4</sub> and R<sub>5</sub>, independently, is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>3</sub>-C<sub>7</sub> cycloalkyl; or a pharmaceutically acceptable salt thereof.

15 2. A compound according to claim 1, wherein

n is 1 or 2;

X is -O-;

each of R, R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub>, independently, is hydrogen, or halogen;

20 R<sub>4</sub> and R<sub>5</sub> are hydrogen.

3. A compound according to claim 1, which is selected from:

2-[4-benzyloxybenzylamino]-2-phenyl-acetamide;

25 2-[4-(3-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide;

2-[4-(3-chlorobenzyloxy)benzylamino]-2-phenyl-acetamide;

2-[4-(3-bromobenzyloxy)benzylamino]-2-phenyl-acetamide;



2-[4-(2-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-2-(2-fluorophenyl)-  
acetamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-  
5 acetamide; and

2-[4-(3-chlorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-  
acetamide, if the case either as a single isomer or as a  
mixture thereof, or a pharmaceutically acceptable salt  
thereof.

10

4. A pharmaceutical composition comprising a  
pharmaceutically acceptable excipient and, as an active  
agent, a compound as defined in claim 1.

15

5. A compound as defined in claim 1, for use in a  
method of treatment of the human or animal body by therapy.

20

6. A compound as claimed in claim 5 for use in  
regulating a physiological condition related to sodium  
channel blockade.

7. A compound as claimed in claim 5, for use in  
treating chronic or neuropathic pain.

25

8. A method of treating a mammal, including a human,  
in need of a sodium channel-blocking agent, said method  
comprising administering thereto an effective amount of a  
compound of formula (I) or a pharmaceutically acceptable  
salt thereof.

30

9. A method according to claim 8 wherein the mammal  
is suffering from chronic or neuropathic pain.

# INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/EP 98/08158

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C237/20 A61K31/16

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 688 830 A (FLIPPIN LEE ALLEN ET AL) 18 November 1997 see claims -----	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 April 1999

Date of mailing of the international search report

03/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Pauwels, G

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/08158

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7,8  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 7,8  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

### Information on patent family members

International Application No.

PCT/EP 98/08158

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5688830 A	18-11-1997	AU 1441797 A WO 9727169 A	20-08-1997 31-07-1997
-----			